No Posts
SKN | Does Eikon Therapeutics’ Nasdaq Debut Signal a Turning Point for Biotech IPOs in 2026?
Eikon Therapeutics’ Nasdaq debut offered a measured, if cautious, snapshot of investor sentiment toward early-stage
- sagi habasov
- •
- 6 Min Read
- •
- 3 months ago












